TABLE 7.
Impact of miRNAs on CSCs in other cancers (ANTs, adjacent non-cancerous tissues).
| Type of cancer | microRNA | Samples | Cell lines | Target | Function | References |
| Clear cell renal cell carcinomas (ccRCC) | miR-106b-5p | Mouse/Human, TCGA database, 20 pairs of ccRCC and ANTs | 786-O, A498, HK-2, ACHN, OSRC-2, Caki-1/2, 769-P | LZTFL1, SFRP1, DKK2, HDAC1, Wnt/β-catenin | miR-106b-5p via activating the Wnt/β-catenin signaling could promote RCC aggressiveness and stem-cell-like phenotype. | Lu et al., 2017b |
| Ovarian cancer (OC) | miR-328–3p | Mouse | OVCAR4, SKOV3, OV2008 | DDB2, Sox2, Nanog, Oct4, ERK1/2 | Disruption of the ROS/ERK/miR-328/DDB2 axis could impair CSC function and prevent metastasis in OC. | Srivastava et al., 2019 |
| Osteosarcoma (OS) | miR-335 | Mouse | MG63, U2OS, 143B, 293T | POU5F1, Sox2 | miR-335 by targeting POU5F1 could regulate OS stem cell-like properties. | Guo et al., 2017 |
| OS | miR-26a | Mouse/Human; tumor samples (n = 53) | U2OS, MG63, Saos-2, 143B, ZOS, ZOSM | Jagged1, Notch, OCT3/4, NANOG, SOX2, c-Myc nucleostemin (NS), CD133, NCID, HES1 | miR-26a/Jagged1/Notch axis could inhibit stem cell-like phenotype and tumor growth of OS. | Lu et al., 2017a |
| Lung Adenocarcinoma (LUAD) | miR-410 | Mouse/Human | Human umbilical cord mesenchymal stem cells (hUCMSCs), H1299, PC-9 | PTEN, CD63, calreticulin, LATS2, HOXA5, Smad4, KLF 10 | The hUCMSC-derived extracellular vesicles by transferring miR-410 could promote LUAD growth. | Dong et al., 2018 |
| LUAD | miR-1275 | Mouse/Human; 196 pairs of LUAD and ANTs | EBAS-2B, L78, H460, A549, GLC-82, SPC-A1, PC9, H1299, H1975, H2228 | DKK3, SFRP1, GSK-3β, RUNX3, NUMB, β-catenin, NICD, HISTH3, Wnt/β-catenin, Notch | HIF-1α-regulated miR-1275 via activating Wnt/β-catenin and Notch could promote the progression of LUAD and maintains stem cell-like features. | Jiang et al., 2020 |
| Non-small cell lung carcinoma (NSCLC) | miR-708-5p | Mouse/Human/TCGA database; NSCLC (n = 148) | A549, Calu-3, 95D | DNMT3A, Dnmt3a, Dnmt3b, p21, 5-mC, CDH1, CD34, D133, Wnt/β-catenin | miR-708-5p by targeting DNMT3A via repressing Wnt/β-catenin signaling could inhibit lung cancer stem cell-like phenotypes. | Liu et al., 2018c |
| NSCLC | has-mir-485-5p | Mouse/Human; Serum samples from NSCLC (n = 16), normal persons (n = 15) | A549, H460, H1299, 293T | RXRα, CD133, CD44, Sox2, Nanog, Oct4, MMP-9, E-cadherin, | Epigallocatechin-3-gallate (EGCG) by modulating the hsa-mir-485-5p/RXRα axis could inhibit CSC-like properties. | Jiang et al., 2018 |
| NSCLC | miR-181b | Mouse/Human/TCGA database; 8 pairs of NSCLC and ANTs | H1650, H1299, A549, A549/DDP | Notch2, Hes1, KLF4, SOX2, NANOG, CD133, ALDH, Caspase-3, Bcl-2, NICD2, HEY1, PARP, PARP | miR-181b by targeting Notch2 could regulate CSC-like properties, and overcome chemoresistance in NSCLC. | Wang et al., 2018 |
| Leukemia/Lymphoma syndrome | miR-339 | Mouse | BBC2, KG1, BaF3, NIH3T3, 293T | BCL-2L11, Bax, FGFR1 | miR-339-5p via downregulation BCL-2L11 and Bax could promote development of Stem cell leukemia/lymphoma (SCLL) syndrome. | Hu et al., 2018 |
| Prostate cancer (PCa) | miR-1301-3p | PCa (n = 136), Normal (n = 22) | N1, N2, 22Rv1, C4-2B, DU-145, LNCap, TSU-PrI, PC-3, α-tubulin, P84 | SFRP1, GSK-3β, OCT4, SOX2, NANOG, CD44, KLF4, c-MYC, MMP2, β-catenin, AKT | miR-1301-3p by targeting GSK-3β and SFRP1 via activating the Wnt pathway could promote expansion of prostate CSCs. | Song et al., 2018 |